479064-89-6 Usage
Uses
Used in Pharmaceutical Research and Development:
FMOC-(S)-3-AMINO-3-(4-FLUORO-PHENYL)-PROPIONIC ACID is used as a building block in the synthesis of peptides and other bioactive molecules, contributing to the development of new pharmaceuticals. Its role in peptide synthesis is facilitated by the protective FMOC group, which can be selectively removed when needed, allowing for the stepwise assembly of complex peptide structures.
Used in Organic Synthesis:
In the field of organic synthesis, FMOC-(S)-3-AMINO-3-(4-FLUORO-PHENYL)-PROPIONIC ACID is used as a versatile intermediate for the creation of a variety of chemical compounds. The presence of the fluoro-phenyl group can influence the reactivity and properties of the resulting molecules, making it a useful component in the synthesis of specialized organic compounds.
Used in Chemical and Biological Applications:
FMOC-(S)-3-AMINO-3-(4-FLUORO-PHENYL)-PROPIONIC ACID is used as a component in various chemical and biological applications due to the potential physical or biological properties imparted by the fluoro-phenyl group. This makes it a candidate for use in the development of new materials, pharmaceuticals, and other bioactive compounds with specific characteristics tailored for particular applications.
Check Digit Verification of cas no
The CAS Registry Mumber 479064-89-6 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 4,7,9,0,6 and 4 respectively; the second part has 2 digits, 8 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 479064-89:
(8*4)+(7*7)+(6*9)+(5*0)+(4*6)+(3*4)+(2*8)+(1*9)=196
196 % 10 = 6
So 479064-89-6 is a valid CAS Registry Number.
InChI:InChI=1/C24H20FNO4/c25-16-11-9-15(10-12-16)22(13-23(27)28)26-24(29)30-14-21-19-7-3-1-5-17(19)18-6-2-4-8-20(18)21/h1-12,21-22H,13-14H2,(H,26,29)(H,27,28)/t22-/m0/s1
479064-89-6Relevant academic research and scientific papers
Solid-phase synthesis of a nonpeptide RGD mimetic library: New selective αvβ3 integrin antagonists
Sulyok,Gibson,Goodman,H?lzemann,Wiesner,Kessler
, p. 1938 - 1950 (2007/10/03)
The solid-phase synthesis of a low molecular weight RGD mimetic library is described. Activities of the compounds in inhibiting the interaction of ligands, vitronectin and fibrinogen, with isolated immobilized integrins αvβ3 and αIIbβ3 were determined in a screening assay. Highly active and selective nonpeptide αvβ3 integrin antagonists with regard to orally bioavailability were developed, based on the aza-glycine containing lead compound 1. An important variation is the substitution of the aspartic amide of 1 by an aromatic residue. Furthermore, different guanidine mimetics have been incorporated to improve the pharmacokinetic profile. Exchange of the β-amino acid NH by a methylene moiety in one set of RGD mimetics leads to the azacarba analogue compounds representing a novel peptidomimetic approach, which should increase the metabolic stability.
